EUROVAC III: European vaccine effort against HIV/AIDS III

• Unité de recherche: PCRD EU
• Numéro de projet: 03.0011
• Titre du projet anglais: EUROVAC III: European vaccine effort against HIV/AIDS III

Mots-clé (Anglais)

Life Sciences; Medicine; Health; Safety; Scientific Research; Social Aspects

Autre Numéro de projet (Anglais)

EU project number: QLK2-CT-2002-01431

Programme de recherche (Anglais)

EU-programme: 5. Frame Research Programme - 1.1.2 Control of infectious diseases

Description succincte (Anglais)

See abstract

Autres indications (Anglais)

Full name of research-institution/enterprise:
Centre hospitalier universitaire vaudois CHUV
Division d'immunologie et d'allergie
Laboratoire d'immunopathologie du SIDA

Résumé des résultats (Abstract) (Anglais)

A vaccine against HIV-1/AIDS is urgently needed to slow down the current epidemic in both Africa and Asia. The predominant subtype of HIV-1 causing the AIDS epidemic in Africa and Asia is subtype C. Clinical lots of priming agents - Semliki Forest virus (SFV) and naked DNA -, as well as a boosting agent - the attenuated poxvirus strain NYV AC -, are prepared; all vaccine components are derived from HIV-1 subtype C and include the gag, pol, nef and env genes. The objective of the EuroVac-III demonstration project is to identify the best priming agent, DNA vs SFV that allows for reduction of the NYVAC dose without significant loss of immunogenicity. This demonstration project aims for the establishment of the most immunogenic vaccine that is suitable for mass vaccination and forms the last step towards moving into phase IIb and III efficacy trials.

Références bases de données (Anglais)

Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. [phone]
Swiss Project-Number: 03.0011